Compare Cassava Sciences Inc (FLNA) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Li Auto Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Li Auto Inc trades at $13.11 (market cap $12.31B). The key difference: Li Auto Inc is far larger — about 231.7× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.
| FLNA | LI | |
|---|---|---|
Market Cap | $53.14M | $12.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $31.80 |
52-Week Low | $1.09 | $11.74 |
Enterprise Value | -$33.43M | $1.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Li Auto (LI) trades at $12.47, up 2.38% today, amid mixed technical signals with a bearish overall trend. The company reported declining revenue from $144.5B in 2024 to $112.3B in 2025, with net income dropping to $1.12B. Recent vehicle deliveries of 30,895 in June 2026 show ongoing operational activity despite competitive pressures in the EV market.
The outlook remains challenging with negative profit margins and high P/E ratio of 99.38, though analyst consensus targets $14.80. Key risks include intense competition and volatile earnings, while potential recovery hinges on successful execution of new models like the Li L8 launched in June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
